Log in
NASDAQ:TSHA

Taysha Gene Therapies Stock Forecast, Price & News

$20.80
+0.88 (+4.42 %)
(As of 10/30/2020 12:00 AM ET)
Add
Compare
Today's Range
$19.50
Now: $20.80▼
$21.53
50-Day Range N/A
52-Week Range
$18.16
Now: $20.80▼
$27.53
Volume174,152 shs
Average Volume220,464 shs
Market Capitalization$744.89 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Taysha Gene Therapies, Inc., a gene therapy company, develops adeno-associated virus based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-101 for the treatment of GM2 gangliosidosis; TSHA-118 for the treatment of CLN1 disease; TSHA-102 for the treatment of Rett syndrome; TSHA-103 for the treatment of SLC6A1 haploinsufficiency disorder; and TSHA-104 for the treatment for Surfeit locus 1 deficiency. The company also has strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. Taysha Gene Therapies, Inc. was founded in 2019 and is based in Dallas, Texas.
Read More

Beat the Market (BTM) Rank™

Analyst Opinion: 3.5Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

0.83 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TSHA
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.tayshagtx.com
Phone214-612-0000
EmployeesN/A

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Outstanding Shares35,812,000
Market Cap$744.89 million
Next Earnings DateN/A
OptionableNot Optionable
$20.80
+0.88 (+4.42 %)
(As of 10/30/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive TSHA News and Ratings via Email

Sign-up to receive the latest news and ratings for TSHA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Taysha Gene Therapies (NASDAQ:TSHA) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Taysha Gene Therapies?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Taysha Gene Therapies in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Taysha Gene Therapies.

What price target have analysts set for TSHA?

4 analysts have issued 12-month price objectives for Taysha Gene Therapies' shares. Their forecasts range from $29.00 to $45.00. On average, they expect Taysha Gene Therapies' stock price to reach $34.75 in the next year. This suggests a possible upside of 67.1% from the stock's current price.
View analysts' price targets for Taysha Gene Therapies.

Who are some of Taysha Gene Therapies' key competitors?

Some companies that are related to Taysha Gene Therapies include SpringWorks Therapeutics (SWTX), Revolution Medicines (RVMD), Editas Medicine (EDIT), Vaxcyte (PCVX), Sorrento Therapeutics (SRNE), Forma Therapeutics (FMTX), Beam Therapeutics (BEAM), AlloVir (ALVR), Replimune Group (REPL), Bavarian Nordic A/S (BVNRY), Kymera Therapeutics (KYMR), Sangamo Therapeutics (SGMO), Cortexyme (CRTX), NanoString Technologies (NSTG) and Mesoblast (MESO).
View all competitors.

Who are Taysha Gene Therapies' key executives?

Taysha Gene Therapies' management team includes the following people:
  • Mr. R. A. Session II, Pres, CEO & Director (Age 41)
  • Mr. Kamran Alam CPA, M.B.A., Chief Financial Officer (Age 42)
  • Mr. Fred Porter Ph.D., Chief Technical Officer
  • Mr. Jim Rouse, Chief Information Officer
  • Dr. Suyash Prasad M.Sc., MBBS, M.D., M.B.B.S., F.F.P.M, Chief Medical Officer and Head of R&D (Age 50)

When did Taysha Gene Therapies IPO?

(TSHA) raised $125 million in an IPO on Thursday, September 24th 2020. The company issued 6,600,000 shares at a price of $18.00-$20.00 per share. Goldman Sachs, Morgan Stanley and Jefferies served as the underwriters for the IPO and Chardan was co-manager.

What is Taysha Gene Therapies' stock symbol?

Taysha Gene Therapies trades on the NASDAQ under the ticker symbol "TSHA."

When does Taysha Gene Therapies' quiet period expire?

Taysha Gene Therapies' quiet period expires on Tuesday, November 3rd. Taysha Gene Therapies had issued 7,869,566 shares in its initial public offering on September 24th. The total size of the offering was $157,391,320 based on an initial share price of $20.00. During Taysha Gene Therapies' quiet period, underwriters and any insiders involved in the IPO are restricted from issuing any research reports for the company because of SEC regulations. Following the end of the company's quiet period, it's expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

How do I buy shares of Taysha Gene Therapies?

Shares of TSHA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Taysha Gene Therapies' stock price today?

One share of TSHA stock can currently be purchased for approximately $20.80.

How big of a company is Taysha Gene Therapies?

Taysha Gene Therapies has a market capitalization of $744.89 million.

What is Taysha Gene Therapies' official website?

The official website for Taysha Gene Therapies is www.tayshagtx.com.

How can I contact Taysha Gene Therapies?

Taysha Gene Therapies' mailing address is 2280 Inwood Road, DALLAS TX, 75235. The company can be reached via phone at 214-612-0000 or via email at [email protected]

This page was last updated on 10/31/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.